Yunnan Baiyao Group Co Ltd
SZSE:000538
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
46.17
62.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co Ltd
Total Liabilities
Yunnan Baiyao Group Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Total Liabilities
¥15B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Liabilities
¥7.2B
|
CAGR 3-Years
35%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Liabilities
¥3.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Liabilities
¥5.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Total Liabilities
¥2B
|
CAGR 3-Years
100%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Liabilities
¥1.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Yunnan Baiyao Group Co Ltd
Glance View
Yunnan Baiyao Group Co Ltd is a well-established Chinese healthcare company renowned for its pioneering products in traditional Chinese medicine, particularly in wound care and pain management. With a rich history dating back to 1902, the company originally gained fame for its unique powder that promotes blood circulation and aids in healing. Over the years, Yunnan Baiyao has evolved into a comprehensive healthcare provider, offering a diverse range of products that span over-the-counter medications, personal care items, and even high-tech medical devices. Its commitment to innovation, backed by a robust research and development framework, has positioned it as a leader in the market, appealing to both traditional and modern healthcare consumers. From an investment standpoint, Yunnan Baiyao stands out as a compelling opportunity due to its strong brand recognition and growing market share in a rapidly expanding healthcare sector. The company consistently showcases impressive financial performance, characterized by robust revenue growth and sustainable profit margins. With the rising demand for effective treatment options fueled by an aging population and increasing health awareness in China, Yunnan Baiyao is strategically positioned to capture this opportunity. As it continues to diversify its product lines and expand internationally, investors may find Yunnan Baiyao to be a promising company that embodies the principles of resilience and adaptability, traits that Warren Buffett and Charlie Munger have long advocated in value investing.
See Also
What is Yunnan Baiyao Group Co Ltd's Total Liabilities?
Total Liabilities
15B
CNY
Based on the financial report for Jun 30, 2024, Yunnan Baiyao Group Co Ltd's Total Liabilities amounts to 15B CNY.
What is Yunnan Baiyao Group Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
14%
Over the last year, the Total Liabilities growth was 13%. The average annual Total Liabilities growth rates for Yunnan Baiyao Group Co Ltd have been 6% over the past three years , 5% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
